Clinical Characteristics and Prognostic Predictors of Pneumocystis Jirovecii Pneumonia in Patients with and without Chronic Pulmonary Disease: A Retrospective Cohort Study
DOI: https://doi.org/10.2147/idr.s456716
2024-05-30
Infection and Drug Resistance
Abstract:Qiuyue Feng, 1, 2 Zhaohui Tong 1 1 Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100020, People's Republic of China; 2 Department of Respiratory and Critical Care Medicine, Beijing Huairou Hospital, Beijing, 101400, People's Republic of China Correspondence: Zhaohui Tong, Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine, Beijing Chaoyang Hospital, Capital Medical University, NO. 8 Gong Ti South Road, Chaoyang District, Beijing, 100020, People's Republic of China, Tel +86 13910930309, Email Objective: Pneumocystis jirovecii pneumonia (PJP) is a severe respiratory infection caused by Pneumocystis jirovecii in immunocompromised hosts. The role of P. jirovecii colonization in the development or progression of various pulmonary diseases has been reported. Our aim was to explore serial change in serum biomarkers and the independent risk factors for mortality in patients with and without chronic pulmonary diseases who developed PJP. Methods: We performed a retrospective study to select patients with Pneumocystis jirovecii pneumonia between January 1, 2012, and December 31, 2021. Information regarding demographics, clinical characteristics, underlying diseases, laboratory tests, treatment, and outcomes was collected. Univariate and multivariate logistic regression analyses were used to identify independent predictors of in-hospital mortality. Results: A total of 167 patients diagnosed with PJP were included in the study: 53 in the CPD-PJP group and 114 in the NCPD-PJP group. The number of patients with PJP showed an increasing trend over the 10-year period. A similar trend was observed for in-hospital mortality. Independent risk factors associated with death in the NCPD-PJP group were procalcitonin level (adjusted OR 1.08, 95% CI 1.01– 1.16, P=0.01), pneumothorax (adjusted OR 0.07, 95% CI 0.01– 0.38, P=0.002), neutrophil count (adjusted OR 1.27, 95% CI 1.05– 1.53, P=0.01) at 14 days, and hemoglobin level (adjusted OR 0.94, 95% CI 0.91– 0.98; P=0.002) at 14 days after admission. The risk factor associated with death in the CPD-PJP group was neutrophil count (adjusted OR 1.19, 95% CI 0.99– 1.43; P=0.05) at 14 days after admission. Conclusion: The risk factors for death were different between patients with PJP with and without chronic pulmonary disease. Early identification of these factors in patients with PJP and other underlying diseases may improve prognosis. Keywords: Pneumocystis jirovecii , pneumonia, chronic pulmonary disease, prognostic factors Pneumocystis jirovecii pneumonia (PJP), also known as Pneumocystis carinii pneumonia, is a fungal disease of the lower respiratory tract caused by Pneumocystis jirovecii . As one of the most serious complications in patients with HIV infection, PJP happened in immunosuppressed and immunocompetent individuals. In recent years, the incidence of PJP in certain non-AIDS immunocompromised patients has increased significantly with the application of massive doses of hormones and novel immunosuppressants. The discovery of the correlation between pneumocystis infection and chronic pulmonary disease has drawn more attention from the medical community. Molecular epidemiological investigations have found that the positive rate of Pneumocystis gene testing in patients with chronic pulmonary diseases such as chronic obstructive pulmonary disease (COPD) was relatively high; therefore, some scholars suspected that Pneumocystis infection was related to the occurrence and development of COPD and other chronic pulmonary diseases, 1 but the cause-and-effect relationship is unclear. 1–3 Several studies have found that infection or colonization of Pneumocystis has an impact on the progression and prognosis of various respiratory diseases, such as chronic airway inflammation, pulmonary cystic fibrosis, and interstitial lung disease. 4–6 Morris et al found that the probability of pulmonary fibrosis and obstructive pulmonary disease was significantly higher in patients with PJP than in those without PJP. 3 Pneumocystis infection increases airway dilation and inflammation in the host, which is aggravated by persistent pneumocystis infection. 7,8 Even a small number of pneumocystis-colonized lungs can stimulate the immune response and cause lung injury. Studies have shown that Pneumocystis colonization is a risk factor for PJP development. 9 The colonization rate of Pneumocystis in the respiratory secretions of chronic bronchitis patients was as high as 41–100%, 10,11 tha -Abstract Truncated-
pharmacology & pharmacy,infectious diseases